登录新浪财经APP 搜索【信披】查看更多考评等级 分券商看，共有65家券商为591家科创板企业提供承销保荐服务，其中中信证券承销数量最多，为99家（含联合承销，下同）；中金公司、中信建投、原海 通证券、华泰联合分别以70家、64家、62家、55家的承销数量位列第二至五位。如果将原国泰君安和海通证券合并计算，国泰海通IPO承销数量为112家， 排名第一。从承销金额看，国泰海通、中信证券、中金公司、中信建投、华泰证券位列前五，承销金额分别为2137.77亿元、1670.69亿元、1302.54亿元、 880.15亿元、622.88亿元，合并后的国泰海通领先优势较大。 科创板开市6年以来，合计有591家公司上市，其中有两家退市，两家被实施退市风险警示，三家被实施其他风险警示。也就是说，591家在科创板上市的公 司中，有7家问题比较严重，占比1.18%，这个概率较低。 有意思的是，三家被ST的公司中，就包括南京证券保荐的ST诺泰（维权）。而南京证券近六年在科创板保荐上市的IPO项目仅有三家，在被ST的概率仅 1.18%的情况下，南京证券在仅有3家项目的情况下竟然"中奖"。 专题：科创板六载沉浮：券商格局生变，谁是赢家 ...

Core Viewpoint - Notai Bio (688076.SH) has been penalized for financial fraud, leading to a downgrade in valuation by fund companies after being designated as ST (Special Treatment) following its resumption of trading [2][7]. Group 1: Financial Fraud and Penalties - The China Securities Regulatory Commission (CSRC) confirmed that Notai Bio's 2021 annual report contained false records, resulting in a total fine of 76.2 million yuan for the company and several executives [2][6]. - Notai Bio's fraudulent activities included inflating revenue by 30 million yuan and profit by 25.95 million yuan, which accounted for 20.64% of the reported total profit for that year [4][5]. - The company was also penalized for providing misleading financial information in its bond issuance documents, leading to additional fines totaling 47.4 million yuan [5][6]. Group 2: Market Impact and Fund Valuation Adjustments - Following the ST designation, Notai Bio's stock closed at 44.51 yuan per share, with a total market capitalization of 14.07 billion yuan [3]. - On July 22, 2025, the valuation of Notai Bio's stock was adjusted to 32.78 yuan by the招商基金, reflecting a reduction of approximately 20% from its previous price of 40.98 yuan [8][9]. - As of the end of Q2 2025, 19 funds from 8 public fund companies held a total of 9.23 million shares of Notai Bio, with a combined market value of 344 million yuan, representing 2.93% of the total share capital [10].

7月22日，科创板多肽巨头诺泰生物（688076.SH）的股票简称正式变更为"ST诺泰"，当日开盘后股价 一度下跌11%。 7月18日，诺泰生物发布公告称，公司收到中国证监会下发的《行政处罚事先告知书》（下称"《事先告 知书》"）。依据《事先告知书》载明内容，根据《上海证券交易所科创板股票上市规则》相关规定， 公司股票7月21日停牌一天，7月22日复牌，简称由"诺泰生物"变更为"ST 诺泰"。 同时，《事先告知书》也揭开了这家明星医药企业财务造假的黑幕。 上市首年就财务造假 诺泰生物前身为"江苏诺泰制药技术有限公司"，2009年在连云港成立，2016年在新三板挂牌，2021年在 科创板上市。 而《事先告知书》显示，诺泰生物2021年年度报告存在虚假记载。也就是说，在科创板上市首年，诺泰 生物就策划了这起财务造假案。 2021年12月，诺泰生物向浙江华贝药业有限责任公司（下称"浙江华贝"）转让药品技术及上市持有许可 人权益（下称"技术转让"），并于12月28日确认业务收入3000万元。 诺泰生物及6名高管合计被处罚7620万元，创下近年来科创板处罚纪录。 南京证券（601990）难辞其咎 作为诺泰生物2021年 ...

Core Viewpoint - The company NuoTai Bio (688076.SH) has been penalized by the China Securities Regulatory Commission (CSRC) for financial fraud and has officially been designated as ST (Special Treatment) due to its violations, which include fabricating financial data and misleading disclosures [1][3]. Group 1: Company Violations - NuoTai Bio was found to have falsely recognized 30 million yuan in revenue through fictitious technology transfers, inflating profits by 25.95 million yuan, which accounted for 20.6% of the disclosed amount [1]. - The company also fabricated significant content in its public offering documents, with the 2023 convertible bond prospectus continuing to use this false data, constituting a serious violation of issuance document integrity [1][3]. Group 2: Underwriter's Responsibility - Nanjing Securities (601990.SH), as the underwriter for NuoTai Bio, was deeply involved in its financing operations and failed to identify the discrepancies in the financial disclosures, despite confirming the accuracy of the information provided [3][6]. - The underwriter received a total of 66.3854 million yuan in underwriting fees for the IPO and an additional 5.66 million yuan for the convertible bond project, raising questions about its due diligence practices [3][6]. Group 3: Regulatory and Market Impact - Following the scandal, Nanjing Securities has faced scrutiny for its oversight quality, with over 40% of the 17 IPO and refinancing companies it has supervised in the past decade encountering issues such as financial fraud and disclosure violations [6]. - Despite achieving a record net profit of 1 billion yuan in 2024, Nanjing Securities reported an 11.6% decline in revenue in the first quarter of 2025, indicating potential weaknesses in its business performance [7]. Group 4: Future Outlook - NuoTai Bio's stock will be subject to additional risk warnings from the Shanghai Stock Exchange, but it does not currently face mandatory delisting due to major legal violations [8]. - Nanjing Securities' 5 billion yuan private placement plan has faced delays and scrutiny, with the validity of the plan extended to July 2026, leaving its future uncertain [8].

Core Viewpoint - The article reveals the fraudulent activities of Nuotai Bio, a company involved in the weight-loss drug sector, which led to its stock suspension and significant penalties from regulatory authorities [1][2]. Group 1: Fraudulent Activities - Nuotai Bio was found to have fabricated transactions in its first year of listing, resulting in a fraudulent issuance of convertible bonds amounting to 434 million yuan [1]. - The company engaged in a scheme where it transferred drug technology to a shell company, Zhejiang Huabei, falsely recognizing revenue of 30 million yuan, while the shell company had no payment capability or production technology [1]. - This "self-financing" scheme inflated Nuotai's profits by 25.95 million yuan, accounting for 20.64% of its total profit for that year [1]. Group 2: Regulatory Actions and Consequences - The China Securities Regulatory Commission (CSRC) imposed a total fine of 76.2 million yuan on Nuotai Bio, including 4 million yuan for false annual report records and 43.4 million yuan for fraudulent issuance [1][2]. - The actual controller, Zhao Dezhong, was fined 18 million yuan, and several executives faced penalties exceeding 10 million yuan collectively [1]. Group 3: Market Impact and Future Outlook - Despite the severity of the fraud, Nuotai Bio did not meet the criteria for mandatory delisting under the new 2024 regulations, as its inflated profits were below the 200 million yuan threshold [2]. - The company will face a prolonged period of risk warning trading, as it must restate its financial reports and wait at least one year to apply for removal of the warning [2]. - The scandal serves as a warning for the booming pharmaceutical outsourcing industry, highlighting the need for vigilance against financial bubbles amid rising capital interest in GLP-1 weight-loss drugs [2].

中国经济网北京7月23日讯 ST诺泰（688076.SH）19日发布关于收到《行政处罚事先告知书》的公告。 ST诺泰于2024年10月22日收到中国证券监督管理委员会（以下简称"中国证监会"）《立案告知书》 （证监立案字0382024093号、证监立案字0382024094号）。根据《立案告知书》，因涉嫌信息披露违法 违规等，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定 立案。 公司于2025年7月18日收到中国证监会下发的《行政处罚事先告知书》（处罚字〔2025〕59号）（以下 简称"《事先告知书》"）。《行政处罚事先告知书》内容如下： 经查，诺泰生物及相关人员违法事实如下： 一、诺泰生物2021年年度报告存在虚假记载 2021年12月，诺泰生物向浙江华贝药业有限责任公司（以下简称浙江华贝）转让药品技术及上市持有许 可人权益（以下简称技术转让），并于12月28日确认业务收入3,000万元。浙江华贝既不具备支付技术 转让款的资金实力，也不具备实际应用该技术的生产能力和销售渠道。同期，诺泰生物策划向浙江华贝 增资。浙江华贝向诺泰生物支付的技术转让款最终来自诺泰生物的增资款。 ...

Core Viewpoint - The article highlights the severe penalties imposed on Nuotai Bio for financial misconduct, including false reporting in its 2021 annual report and significant inaccuracies in its public offering documents, reflecting serious internal governance issues [1][4][8]. Financial Penalties and Market Reaction - Nuotai Bio was fined 47.4 million yuan and its actual controller, Zhao Dezhong, was fined 13 million yuan due to violations in financial reporting [1][2]. - Following the announcement, the stock price dropped over 11% upon resuming trading, closing at 39.22 yuan per share, a decline of 4.29% from the last trading day before suspension [2]. Internal Governance Issues - The financial discrepancies stemmed from a questionable technology transfer deal with Zhejiang Huabei, which was not a legitimate transaction, leading to inflated revenue and profit figures in the 2021 annual report [5][6]. - The internal management flaws have been previously noted, with past regulatory warnings indicating ongoing issues with governance and compliance [7][8]. Business Performance and Growth - Despite the recent controversies, Nuotai Bio has shown significant growth in revenue, increasing from 371 million yuan in 2019 to 1.625 billion yuan in 2024, with a net profit rise from 49 million yuan to 404 million yuan [10][11]. - The company has established strategic partnerships in the GLP-1 drug sector, contributing to its revenue growth and positioning in the market [11][12]. Industry Context and Future Outlook - The demand for peptide drugs is surging, with Nuotai Bio positioned to benefit from this trend, although concerns about overcapacity in the peptide sector exist [12][13]. - The company faces a dual challenge of capitalizing on market opportunities while addressing internal governance issues that could undermine investor confidence [13].

诺泰生物因财务造假问题于7月21日停牌一天。7月22日复牌后被实施其他风险警示。公司股票简称正式变更为"ST诺泰"。这一监管措施源于中国证监会下发 的《行政处罚事先告知书》。该告知书显示公司在2021年年报中存在虚假记载。同时在可转换公司债券发行文件中编造重大虚假内容。 招商基金等多家公募基金管理人持有诺泰生物股票。根据基金已发布的二季报数据显示。截至上半年末近20只产品持有诺泰生物股票。合计持股市值超过 3.4亿元。招商基金旗下10只产品合计持股733.06万股。占诺泰生物流通A股的比例为2.46%。 王景管理的招商蓝筹精选股票持有诺泰生物约1.02亿元。招商制造业转型灵活配置混合持有6907万元。招商品质升级混合持有5191万元。环比均有不同程度 的增长。国寿安保基金、宏利基金等机构也有相关持仓。 中国证监会拟对诺泰生物责令改正并给予警告。处以4740万元罚款。对实际控制人赵德中给予警告。并处以1300万元罚款。其中作为直接负责的主管人员处 以500万元罚款。作为实际控制人组织指使上述行为处以800万元罚款。对其他相关责任人给予警告并处以不同金额的罚款。公司及6名高管合计被处罚7620 万元。 来源:金融 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 长江商报消息 ●长江商报记者 沈右荣 财务造假案曝光，7月22日复牌后，科创板公司诺泰生物（688076.SH）被ST。 近日，诺泰生物公告，公司收到了中国证监会下发的《行政处罚事先告知书》（简称《事先告知 书》）。 证监会经调查确认，2021年，诺泰生物存在财务造假行为，即通过不具有交易实质的交易虚构营业收入 3000万元，虚构利润总额2595.16万元。在2023年的可转换公司债券文件中，存在编造2021年营业收 入、利润总额重大虚假内容。证监会拟对诺泰生物罚款4740万元，拟对实际控制人赵德中、赵德毅罚款 合计1800万元。其他相关责任人也将被处以罚款。 2021年，诺泰生物登陆科创板。也就是说，在上市首年，公司就策划了这起财务造假案。 诺泰生物的实际控制人为赵德毅、赵德中兄弟，二人热衷资本运作，驱动诺泰生物资产规模快速扩大。 但随之而来的是，诺泰生物财务承压。截至2025年一季度末，公司资产负债率47.76%，较2021年底的 不到15%大幅攀升。 诺泰生物财务造假，基金踩雷。Wind数据显示，根据基金陆续披露的半年报，至少有9家基金公司踩 雷。其中， ...

星标 ★ IPO日报 精彩文章第一时间推送 近日，江苏诺泰澳赛诺生物制药股份有限公司（下称"诺泰生物"，688076.SH）收到了中国证监会下发 的《行政处罚事先告知书》。根据《行政处罚事先告知书》，因涉及2021年年度报告存在虚假记载、公 开发行文件编造重大虚假内容，诺泰生物被罚4740万元，相关责任人被处以150万元至1300万元不等的 罚款。 此外，公司股票将于7月22日起复牌，自复牌之日起实施其他风险警示，证券简称变为ST诺泰。实施风 险警示期间，公司股票不进入上海证券交易所风险警示板交易，不适用风险警示板交易的相关规定。公 司股票的涨跌幅限制不变，仍为20%。 AI制图 财务造假 具体来看，2021年12月，诺泰生物向浙江华贝药业有限责任公司（下称"浙江华贝"）转让药品技术及上 市持有许可人权益，并于2021年12月28日确认业务收入3000万元。同期，诺泰生物策划向浙江华贝增 资。 但实际上，浙江华贝既不具备支付技术转让款的资金实力，也不具备实际应用上述转让技术的生产能力 和销售渠道。浙江华贝向诺泰生物支付的技术转让款，最终来自诺泰生物的增资款。诺泰生物的上述业 务导致其2021年年报虚增营业收入 ...